V. Trillet-Lenoir - Concepedia

Author

V. Trillet-Lenoir

Also Known As

B. Tranchand, P. Tresca, Trillet-Lenoir V, Trillet-Lenoir, Veronique, Trillet-Lenoir, Véronique, V Trillet-Lenoir, V. N. Trillet-Lenoir, V. Trillet-Lenoir, Veronique N. Trillet-Lenoir, Veronique Trillet-Lenoir

163

Publications

Citations

H-Index

Concepts

All Affiliations

Hôpital Lyon Sud Université Claude Bernard Lyon 1 Hospices Civils de Lyon Centre Léon Bérard Inserm

About

V. Trillet-Lenoir is an author at Hôpital Lyon Sud specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	28	1.9K
2	Health Sciences	8	8	809
3	Nursing	2	2	35
4	Public Health	1	1	46
5	Social Sciences	1	1	45

V. Trillet-Lenoir

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy V. Trillet-Lenoir, J. Green, C. Manegold, European Journal of Cancer Hematological MalignancyGranulocyteMedicineInfectious ComplicationsImmunology	1993	545
Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy Jean‐Marc Nabholtz, H.-J. Senn, W.R. Bezwoda, Journal of Clinical Oncology	1999	506
Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure and Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis: Morbidity and Mortality Analysis of 216 Consecutive Procedures Olivier Gléhen, D. Osinsky, Eddy Cotte, Annals of Surgical Oncology Surgical OncologyIntraperitoneal ChemohyperthermiaGastrointestinal OncologyConsecutive ProceduresMedicine	2003	341
Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial Bruno Coudert, Rémy Largillier, Laurent Arnould, Journal of Clinical Oncology	2007	132
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial Xavier Pivot, Gilles Romieu, Marc Debled, The Lancet Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer	2019	125
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site P. Sève, Isabelle Ray‐Coquard, V. Trillet-Lenoir, Cancer	2006	114
Addition of Oxaliplatin to Continuous Fluorouracil, <scp>l</scp>-Folinic Acid, and Concomitant Radiotherapy in Rectal Cancer: The Lyon R 97-03 Phase I Trial Gilles Freyer, Nadine Bossard, P. Romestaing, Journal of Clinical Oncology	2001	103
Hypersensitivity to oxaliplatin: clinical features and risk factors Marie Parel, Florence Ranchon, Audrey Nosbaum, BMC Pharmacology and Toxicology	2014	103
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure Gilles Freyer, P Rougier, R. Bugat, British Journal of Cancer	2000	89
Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole Vincent Cottin, D. Arpin, Christine Lasset, Annals of Oncology Patient PopulationMedicineCancer ManagementClinical TrialsPathology	1999	77

Page 1